Jönsson P, Ohlsson K
Department of Surgical Pathophysiology, University of Lund, Malmö General Hospital, Sweden.
Scand J Clin Lab Invest. 1995 May;55(3):223-7. doi: 10.3109/00365519509089617.
Experimental porcine pancreatitis was induced by the injection of taurocholate into the pancreatic duct. Recombinant human pancreatic secretory trypsin inhibitor (25 mg) was administered to each animal in one of three different ways: into the pancreatic duct (n = 5), into the abdominal cavity adjacent to the pancreas (n = 2) or intravenously (n = 2). The intrapancreatic turnover was assessed during 6 h using a microdialysis technique. The intraglandular concentration, measured by enzyme-linked immunosorbent assay, was highest after injection of rhPSTI into the pancreatic duct and substantially lower after intravenous and intraperitoneal administration. The intrapancreatic half-life of the inhibitor after intraductal administration was considerably longer (3-6 times) in pigs with pancreatitis than has previously been found in the normal gland. These facts argue in favour of the intraductal administration route in future trials of antiprotease treatment in acute pancreatitis.
通过向胰管注射牛磺胆酸盐诱导实验性猪胰腺炎。将重组人胰分泌性胰蛋白酶抑制剂（25毫克）以三种不同方式之一给予每只动物：注入胰管（n = 5）、注入胰腺附近的腹腔（n = 2）或静脉内注射（n = 2）。使用微透析技术在6小时内评估胰腺内周转率。通过酶联免疫吸附测定法测量的腺体内浓度，在将重组人胰分泌性胰蛋白酶抑制剂注入胰管后最高，而在静脉内和腹腔内给药后则显著降低。与先前在正常腺体中发现的情况相比，胰腺炎猪在导管内给药后抑制剂的胰腺内半衰期长得多（3至6倍）。这些事实支持在未来急性胰腺炎抗蛋白酶治疗试验中采用导管内给药途径。
